Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03768063 · ClinicalTrials.gov registry record · Phase 3
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
A Phase 3 study of Cancer, sponsored by Hoffmann-La Roche.
- Active
- Registry status
- Phase 3
- Development phase
- 1,000
- Enrollment target
- 20
- Study locations
NCT03768063: Active Phase 3 study of Cancer, sponsored by Hoffmann-La Roche.
NCT03768063 is a Phase 3 study of Cancer that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 1,000 participants, below the 3,489-participant average among 615 other Cancer trials with a reported enrollment target (71% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03768063, a Phase 3 study of Cancer, is active but no longer recruiting, sponsored by Hoffmann-La Roche.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open-label, multicenter, extension study. Patients who are receiving clinical benefit from atezolizumab monotherapy or atezolizumab in combination with other agent(s) or combination/comparator agent(s) during participation in a Genentech or Roche-sponsored study (the parent study), who are eligible to continue treatment and who do not have access to the study treatment locally, may continue to receive study treatment in this extension study following roll-over from the parent study.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Atezolizumab
- DRUG Vemurafenib
- DRUG Alectinib
- DRUG Cobimetinib
Study Locations (20)
Other
- Institut Jules Bordet - Brussels
- UZ Brussel - Brussels
- Multiprofile Hospital for Active Treatment Central Onco Hospital OOD - Plovdiv
- Pontificia Universidad Catolica de Chile - Santiago
- Masaryk?v onkologický ústav - Brno
- Rigshospitalet - København Ø
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
Colorado
- University of Colorado Cancer Center - Aurora
Connecticut
- Yale University School Of Medicine - Trumbull
Florida
- Advent Health Orlando - Maitland
North Carolina
- Carolina BioOncology Institute, PLCC - Huntersville
Pennsylvania
- St. Luke's Cancer Care Associates - Bethlehem
Texas
- University of Texas Health Sciences Center in San Antonio - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2019-02-28 |
| Est. Completion | 2028-07-05 |
| Phase | Phase 3 |
What the registry record for NCT03768063 still lists
NCT03768063 is an interventional study that assigns participants to a tested intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, below the 3,489-participant average among 615 other Cancer trials with a reported enrollment target (71% lower).
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 5 interventions - of which Bevacizumab is the first listed.
NCT03768063 names 20 study sites across 14 states, led by Other, Massachusetts, Colorado.
Frequently Asked Questions
What is clinical trial NCT03768063 about?
NCT03768063 is a clinical study titled "A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study". This is an open-label, multicenter, extension study. Patients who are receiving clinical benefit from atezolizumab monotherapy or atezolizumab in combination with other agent(s) or combination/comparator agent(s) during participation in a Genentech or Roche-sponsored study (the parent study), who ar...
What is the current status of trial NCT03768063?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,000 participants. The study started on 2019-02-28. Estimated completion is 2028-07-05.
What conditions does trial NCT03768063 study?
This clinical trial studies the following conditions: Cancer.
What interventions are being tested in trial NCT03768063?
The interventions under investigation include: Bevacizumab (DRUG), Atezolizumab (DRUG), Vemurafenib (DRUG), Alectinib (DRUG), Cobimetinib (DRUG).
Who is sponsoring clinical trial NCT03768063?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03768063 being conducted?
This trial has 20 study locations across Colorado, Connecticut, Florida, Massachusetts, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03768063's enrollment target sits among peer trials
1,000 80th of 615 higher than 531 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Spiritual Care or Psychotherapy Versus Palliative Care Alone in Patients With Non-Curative Malignancies
RECRUITING · Phase 3
-
DOAC - Dosing Options in AntiCoagulation Prophylaxis
RECRUITING · Phase 3
-
Abatacept in Immune Checkpoint Inhibitor Myocarditis
RECRUITING · Phase 3
-
Post-Discharge Risk-Based Management in Patients Undergoing High-Risk Elective Major Cancer Operations (PRS II)
RECRUITING · Phase 3
-
A Randomized Controlled Trial of Inhaled Tranexamic Acid for the Treatment of Pulmonary Hemorrhage in Cancer Patients
RECRUITING · Phase 3
-
Evaluation of a Telehealth Oncofertility Care Intervention in Adolescent and Young Adult Cancer Patients
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI